Role of the JAK-STAT pathway in myocardial injury

Trends in Molecular Medicine

Volumn 13, Issue 2, 2007, Pages 82-89

  Barry, Seán P ^a   Townsend, Paul A ^b   Latchman, David S ^a   Stephanou, Anastasis ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN;

ANGIOGENESIS; APOPTOSIS; CELL DAMAGE; CONTROLLED STUDY; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; HYPERTROPHY; ISCHEMIA; ISCHEMIC HEART DISEASE; ISCHEMIC PRECONDITIONING; MYOCARDITIS; NONHUMAN; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY; REVIEW; VIRUS MYOCARDITIS;

ANIMALS; APOPTOSIS; CARDIOMEGALY; HEART DISEASES; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; JANUS KINASES; MODELS, CARDIOVASCULAR; MYOCARDIAL REPERFUSION INJURY; MYOCARDITIS; NEOVASCULARIZATION, PATHOLOGIC; STAT TRANSCRIPTION FACTORS;

EID: 33846815097     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.12.002     Document Type: Review

References (75)

1. Eefting F. Role of apoptosis in reperfusion injury. Cardiovasc. Res. 61 (2004) 414-426
2. Zhao Z.Q. Oxidative stress-elicited myocardial apoptosis during reperfusion. Curr. Opin. Pharmacol. 4 (2004) 159-165
3. O'Shea J.J., et al. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109 Suppl (2002) S121-S131
4. Levy D.E., and Darnell Jr. J.E. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3 (2002) 651-662
5. Meyer T., et al. DNA binding controls inactivation and nuclear accumulation of the transcription factor Stat1. Genes Dev. 17 (2003) 1992-2005
6. Zhong M., et al. Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle. Proc. Natl. Acad. Sci. 102 (2005) 3966-3971
7. Meyer T., and Vinkemeier U. Nucleocytoplasmic shuttling of STAT transcription factors. Eur. J. Biochem. 271 (2004) 4606-4612
8. Shen Y., et al. Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol. Cell. Biol. 24 (2004) 407-419
9. Varinou L., et al. Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-γ-dependent innate immunity. Immunity 19 (2003) 793-802
10. Shen Y., et al. Reduced STAT3 activity in mice mimics clinical disease syndromes. Biochem. Biophys. Res. Commun. 330 (2005) 305-309
11. 2+ and CaMKII for Stat1 Ser-727 phosphorylation in response to IFN-γ. Proc. Natl. Acad. Sci. U.S.A 99 (2002) 5971-5976
12. Uddin S., et al. Protein kinase C-δ (PKC-δ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J. Biol. Chem. 277 (2002) 14408-14416
13. Ramsauer K., et al. p38 MAPK enhances STAT1-dependent transcription independently of Ser-727 phosphorylation. Proc. Natl. Acad. Sci. U.S.A 99 (2002) 12859-12864
14. Kovarik P., et al. Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-γ uses a different signaling pathway. Proc. Natl. Acad. Sci. U.S.A 96 (1999) 13956-13961
15. Schuringa J.J., et al. Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components. Biochem. J. 347 (2000) 89-96
16. Bromberg J.F., et al. Stat3 as an oncogene. Cell 98 (1999) 295-303
17. Shen Y., et al. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc. Natl. Acad. Sci. U.S.A 98 (2001) 1543-1548
18. Haga S., et al. Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J. Clin. Invest. 112 (2003) 989-998
19. Niu G., et al. Role of Stat3 in regulating p53 expression and function. Mol. Cell. Biol. 25 (2005) 7432-7440
20. Turkson J., et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol. Cancer Ther. 3 (2004) 1533-1542
21. Kortylewski M., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11 (2005) 1314-1321
22. Chin Y.E., et al. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol. Cell. Biol. 17 (1997) 5328-5337
23. Kramer O.H., et al. Acetylation of Stat1 modulates NF-κB activity. Genes Dev. 20 (2006) 473-485
24. Wang Y., et al. Stat1 as a component of tumor necrosis factor α receptor 1-TRADD signaling complex to inhibit NF-κB activation. Mol. Cell. Biol. 20 (2000) 4505-4512
25. Wencker D., et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J. Clin. Invest. 111 (2003) 1497-1504
26. Narula J., et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A 96 (1999) 8144-8149
27. Scheubel R.J., et al. Apoptotic pathway activation from mitochondria and death receptors without caspase-3 cleavage in failing human myocardium: fragile balance of myocyte survival?. J. Am. Coll. Cardiol. 39 (2002) 481-488
28. Kang P.M., and Izumo S. Apoptosis and heart failure: a critical review of the literature. Circ. Res. 86 (2000) 1107-1113
29. Cook S.A., et al. Regulation of bcl-2 family proteins during development and in response to oxidative stress in cardiac myocytes: association with changes in mitochondrial membrane potential. Circ. Res. 85 (1999) 940-949
30. Mocanu M.M., et al. Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br. J. Pharmacol. 130 (2000) 197-200
31. Negoro S., et al. Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc. Res. 47 (2000) 797-805
32. Kunisada K., et al. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A 97 (2000) 315-319
33. Negoro S., et al. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 104 (2001) 979-981
34. Oshima Y., et al. STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc. Res. 65 (2005) 428-435
35. Takeda K., et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. U.S.A 94 (1997) 3801-3804
36. Hilfiker-Kleiner D., et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ. Res. 95 (2004) 187-195
37. Harada M., et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat. Med. 11 (2005) 305-311
38. Komine-Kobayashi M., et al. Neuroprotective effect of recombinant human granulocyte colony-stimulating factor in transient focal ischemia of mice. J. Cereb. Blood Flow Metab. 26 (2006) 402-413
39. Zhang X., et al. Carbon monoxide differentially modulates STAT1 and STAT3 and inhibits apoptosis via a phosphatidylinositol 3-kinase/Akt and p38 kinase-dependent STAT3 pathway during anoxia-reoxygenation injury. J. Biol. Chem. 280 (2005) 8714-8721
40. Stephanou A., et al. Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis. J. Biol. Chem. 275 (2000) 10002-10008
41. McCormick J., et al. Free radical scavenging inhibits STAT phosphorylation following in vivo ischemia/reperfusion injury. FASEB J. 20 (2006) 2115-2117
42. Takagi Y., et al. STAT1 is activated in neurons after ischemia and contributes to ischemic brain injury. J. Cereb. Blood Flow Metab. 22 (2002) 1311-1318
43. Townsend P.A., et al. Epigallocatechin-3-gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/reperfusion-induced apoptosis. FASEB J. 18 (2004) 1621-1623
44. Costa-Pereira A.P., et al. Mutational switch of an IL-6 response to an interferon-γ-like response. Proc. Natl. Acad. Sci. U.S.A 99 (2002) 8043-8047
45. Qing Y., and Stark G.R. Alternative activation of STAT1 and STAT3 in response to interferon-γ. J. Biol. Chem. 279 (2004) 41679-41685
46. Xuan Y.T., et al. Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J. Mol. Cell. Cardiol. 35 (2003) 525-537
47. Xuan Y.T., et al. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc. Natl. Acad. Sci. U.S.A 98 (2001) 9050-9055
48. Xuan Y.T., et al. Role of the protein kinase C-ε-Raf-1-MEK-1/2-p44/42 MAPK signaling cascade in the activation of signal transducers and activators of transcription 1 and 3 and induction of cyclooxygenase-2 after ischemic preconditioning. Circulation 112 (2005) 1971-1978
49. Smith R.M., et al. Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovasc. Res. 63 (2004) 611-616
50. Hattori R., et al. Role of STAT3 in ischemic preconditioning. J. Mol. Cell. Cardiol. 33 (2001) 1929-1936
51. Dawn B., et al. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc. Res. 64 (2004) 61-71
52. Xuan Y.T., et al. Nuclear factor-κB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ. Res. 84 (1999) 1095-1109
53. Lecour S., et al. Pharmacological preconditioning with tumor necrosis factor-α activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 112 (2005) 3911-3918
54. Smith R.M. Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNF-α gene. Cardiovasc. Res. 55 (2002) 553-560
55. Kuhl U., et al. Parvovirus B19 infection mimicking acute myocardial infarction. Circulation 108 (2003) 945-950
56. Yasukawa H., et al. The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. J. Clin. Invest. 111 (2003) 469-478
57. Yajima T., et al. Innate defense mechanism against virus infection within the cardiac myocyte requiring gp130-STAT3 signaling. Circulation 114 (2006) 2364-2373
58. Frey N., et al. Hypertrophy of the heart: a new therapeutic target?. Circulation 109 (2004) 1580-1589
59. Pan J., et al. Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. Circ. Res. 84 (1999) 1127-1136
60. Hirota H., et al. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc. Natl. Acad. Sci. U.S.A 92 (1995) 4862-4866
61. Ancey C., et al. Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation. Cardiovasc. Res. 59 (2003) 78-85
62. Hirota H., et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97 (1999) 189-198
63. Kunisada K., et al. Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation 98 (1998) 346-352
64. Yasukawa H., et al. Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways. J. Clin. Invest. 108 (2001) 1459-1467
65. Podewski E.K., et al. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation 107 (2003) 798-802
66. Funamoto M., et al. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J. Biol. Chem. 275 (2000) 10561-10566
67. Osugi T., et al. Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J. Biol. Chem. 277 (2002) 6676-6681
68. Yahata Y., et al. Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J. Biol. Chem. 278 (2003) 40026-40031
69. Battle T.E., et al. Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res. 66 (2006) 3649-3657
70. Yang X.P., et al. Signal transducer and activator of transcription 3α and specificity protein 1 interact to upregulate intercellular adhesion molecule-1 in ischemic-reperfused myocardium and vascular endothelium. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1395-1400
71. Guaiquil V.H., et al. Vitamin C inhibits hypoxia-induced damage and apoptotic signaling pathways in cardiomyocytes and ischemic hearts. Free Radic. Biol. Med. 37 (2004) 1419-1429
72. Stephanou A., et al. The carboxyl-terminal activation domain of the STAT-1 transcription factor enhances ischemia/reperfusion-induced apoptosis in cardiac myocytes. FASEB J. 16 (2002) 1841-1843
73. Nam S., et al. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc. Natl. Acad. Sci. U.S.A 102 (2005) 5998-6003
74. Turkson J., et al. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J. Biol. Chem. 280 (2005) 32979-32988
75. Meyer T., et al. DNA binding controls inactivation and nuclear accumulation of the transcription factor Stat1. Genes Dev. 17 (2003) 1992-2005